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OBJECTIVE — Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine
(SDMA), and L-arginine directly inﬂuence nitric oxide production. Our objective was to test
whetherserumADMA,SDMA,or L-argininelevelscorrelatewithdiabeticretinopathysubtypeor
severity.
RESEARCH DESIGN AND METHODS — A total of 162 subjects with type 1 diabetes
and 343 with type 2 diabetes, of whom 329 subjects had no diabetic retinopathy, 27 had
nonproliferative diabetic retinopathy (NPDR), 101 had proliferative diabetic retinopathy (PDR),
and 107 had clinically signiﬁcant macular edema (CSME), were recruited. Blinding diabetic
retinopathy was deﬁned as severe NPDR, PDR, or CSME. Serum ADMA, SDMA, and L-arginine
concentrations were determined by mass spectroscopy.
RESULTS — In multivariate analysis, blinding diabetic retinopathy, PDR, and nephropathy
were associated with signiﬁcantly increased serum levels of ADMA (P  0.001), SDMA (P 
0.001), and L-arginine (P  0.001). Elevated ADMA (P  0.001) and SDMA (P  0.001) were
also signiﬁcantly associated with CSME.
CONCLUSIONS — Severe forms of diabetic retinopathy are associated with elevated serum
ADMA, SDMA, and L-arginine. Further investigation is required to determine whether these
ﬁndings are of clinical relevance.
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E
ndothelialdysfunctionandimpaired
ocular hemodynamics underlying
diabetic retinopathy development
are associated with decreased nitric oxide
(NO) synthase activity and NO bioavail-
ability, resulting in vasoconstriction and
increased reactive oxygen species (1).
Serum asymmetric dimethylarginine
(ADMA), symmetric dimethylarginine
(SDMA), and L-arginine are involved in
the NO pathway, directly inﬂuencing NO
production. This study investigated the
association between diabetic retinopathy
subtypes and serum levels of ADMA,
SDMA,and L-arginineinanAustralianco-
hort of 505 subjects with type 1 or type 2
diabetes.
RESEARCH DESIGN AND
METHODS— Subjectswererecruited
from ophthalmology and endocrinology
outpatient clinics of three tertiary hospi-
tals in Adelaide, South Australia. Ethics
approval was obtained from the relevant
HumanResearchEthicsCommittees.The
cohortconsistedof162subjectswithtype
1 and 343 with type 2 diabetes. Retinop-
athy status for the worst eye was graded
according to the Early Treatment and Di-
abetic Retinopathy Study criteria (2). If
either eye had clinically signiﬁcant macu-
lar edema (CSME), irrespective of other
diabetic retinopathy gradings, the patient
wasalsoclassiﬁedashavingCSME.Blind-
ing retinopathy was deﬁned as severe
nonproliferative diabetic retinopathy
(NPDR), proliferative diabetic retinopa-
thy (PDR), or CSME.
Blood pressure and BMI were mea-
sured. Renal function tests (serum creati-
nine, urine albumin, and albumin-to-
creatinine ratio), serum cholesterol, and
A1C levels (mean of three recent levels)
were obtained. Patients were classiﬁed as
hypertensive if they were on antihyper-
tension medication or had a blood pres-
sure 140/90 mmHg at recruitment.
Hypercholesterolemia was deﬁned as to-
tal cholesterol 5.5 mmol/l or current
use of lipid-lowering medication. Ne-
phropathy was deﬁned as urine albumin
30 mg/day.
Serumconcentrationsofarginineand
its dimethylated metabolites ADMA and
SDMA were determined by liquid chro-
matography–tandem mass spectrometry
of the butyl esters (3) on an Applied Bio-
systems 3200 Q-Trap instrument (Ap-
plied Biosystems, Scoresby, Victoria).
Statistical analyses were undertaken
inSPSS(version15.0;SPSS,Chicago,IL).
A P value 0.05 was considered signiﬁ-
cant. Baseline clinical characteristics of
case and control subjects were compared
using the t test or 
2 tests as appropriate.
Serum ADMA, SDMA, and L-arginine
concentrationswerelogtransformed,and
association with diabetic retinopathy was
assessedbyahierarchicalmultipleregres-
sion procedure for multivariate analysis.
RESULTS— Of 505 participants, 330
had no diabetic retinopathy (105 of
whom were type 1 and 225 type 2 dia-
betic) and 175 were classiﬁed as having
blinding diabetic retinopathy (57 type 1
and 118 type 2 diabetic). In the blinding
diabeticretinopathygroup,27hadsevere
NPDR (4 type 1 and 23 type 2 diabetic),
101 PDR (42 type 1 and 59 type 2 dia-
betic), and 108 CSME (26 type 1 and 82
type 2 diabetic).
Disease duration, sex, age, hyperten-
sion, hypercholesterolemia, nephropa-
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with diabetic retinopathy (P  0.05).
Blinding diabetic retinopathy (Fig. 1) and
PDR were strongly associated with ele-
vated serum ADMA (P  0.001), SDMA
(P  0.001), and L-arginine (P  0.001)
afteradjustmentforassociatedcovariates.
In type 1 diabetic subjects, blinding dia-
betic retinopathy was associated with sig-
niﬁcantly increased ADMA (P  0.001)
and SDMA (P  0.001). In patients with
type 1 diabetes and PDR, there was a
strong association with ADMA (P 
0.001) and SDMA (P  0.001) and a bor-
derline association with L-arginine (P 
0.04). In type 2 diabetic subjects, both
blinding diabetic retinopathy and PDR
were signiﬁcantly associated with ele-
vated ADMA and SDMA (P  0.013 and
P  0.001, respectively, for blinding dia-
betic retinopathy and P  0.014 and P 
0.001, respectively, for PDR). CSME was
signiﬁcantly associated with elevated
ADMA (P  0.001) and SDMA (P 
0.001) when both types of diabetes were
combined. However, in subjects with
type1diabetesalone,onlySDMAshowed
a signiﬁcant elevation (P  0.001), and
no signiﬁcant association of the analytes
withCSMEintype2diabeticsubjectswas
found.
Age, disease duration, hypertension,
BMI, hypercholesterolemia, smoking,
anddiabeticretinopathywerefoundtobe
signiﬁcantly correlated with nephropathy
(P  0.05). Nephropathy was associated
with ADMA (P  0.001), SDMA (P 
0.001), and L-arginine (P  0.001) after
adjustment for associated covariates. All
three analytes were associated with ne-
phropathyintype1diabetes(ADMA,P
0.001; SDMA, P  0.001; L-arginine, P 
0.034). However, only ADMA (P  0.03)
and SDMA (P  0.001) were associated
with nephropathy in type 2 diabetes.
The mean levels of all three analytes
in participants with blinding diabetic ret-
inopathy (but with nephropathy subjects
excluded [n110]) were compared with
the mean levels in those with nephropa-
thy (but with blinding diabetic retinopa-
thy subjects excluded [n  68]), and no
signiﬁcant differences were found (P 
0.5).
CONCLUSIONS— ADMA, SDMA,
and L-arginineareinvolvedintheproduc-
tion of NO, a key player in both micro-
vascular damage pathogenesis and
diabetic retinopathy (1). We found that
all three are signiﬁcantly elevated in pa-
tients with blinding diabetic retinopathy
and PDR, irrespective of diabetes type.
This study is the ﬁrst to report an associ-
ation between elevated levels of ADMA
and SDMA with CSME.
Fourpreviousstudiesinvestigatedse-
rum ADMA levels in diabetic retinopathy
(4–7).ThreereportedelevationofADMA
in diabetic retinopathy participants (4–
6). Only Malecki et al. (5) assessed the
association of both SDMA and L-arginine
with diabetic retinopathy in type 2 diabe-
tes, ﬁnding an association of SDMA with
diabetic retinopathy. Tarnow et al. (7)
found that ADMA levels were not signiﬁ-
cantly increased in any form of diabetic
retinopathy in 600 subjects with type 1
diabetes. Our study was deliberately en-
riched with subjects with blinding dia-
betic retinopathy so differences in
diabetic retinopathy phenotype affecting
study power may be factors in the
comparison.
The effect of nephropathy on diabetic
retinopathy (8,9) could potentially be
mediated by elevated dimethylarginines
because all three analytes are renally
cleared and ADMA and SDMA are ele-
vated by reduced renal clearance (7,10).
We observed a signiﬁcant association of
all three analytes with nephropathy. Se-
rum SDMAs in patients with nephropa-
thy, especially end-stage nephropathy,
are known to be markedly higher than
ADMAs (10,11). Similarly, we found
higher SDMA levels compared with
ADMA levels in participants with ne-
phropathy in addition to retinopathy.
One possibility is that decreased renal
clearance of these analytes may lead to
elevated serum concentrations directly
impacting diabetic retinopathy develop-
ment. Other factors that could inﬂuence
ADMA include hyperglycemia-induced
inhibition of dimethylarginine dimethyl-
aminohydrolase, which degrades ADMA
(12); the effects of insulin resistance (13);
ormedications,includingoralhypoglyce-
mic agents (13,14) and ACE inhibitors
(15). Further prospective and functional
studies are required to investigate the
clinical and pathological signiﬁcance of
elevated ADMA, SDMA, and L-arginine in
Figure 1—Box plots of untransformed concentrations of L-arginine, ADMA, and SDMA (mol/l) in all subjects without diabetic retinopathy (DR)
(n  330) and blinding diabetic retinopathy (n  175) are shown, regardless of type of diabetes. Data are shown as the 25th, 50th, and 75th
percentiles (represented by gray boxes), range (shown as whiskers; outliers have been removed), and the median (white horizontal line). Means 
SD and adjusted P values for each analyte are provided under the corresponding box plot. P values have been adjusted for type of diabetes, diabetes
duration, age, hypertension, hypercholesterolemia, and nephropathy.
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